WHITEHAWK THERAPEUTICS INC
WHWKNASDAQ🏆 #3680 by market capEarnings Nov 5US Equity
$527.74▼ $23.12 (−4.38%)
Simulated priceTrack WHWK
Get earnings, price moves & breaking news on Telegram
24h▼ 4.4%
7d▲ 12930.6%
14d▲ 12740.4%
30d▲ 11249.2%
ytd▲ 21662.5%
1y▲ 27458.2%
🏦Market Cap
$214M
Small Cap
📈Revenue Growth (YoY)
-72.5%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $525.98 – $537.52
- 52-Week Range
- $1.82 – $5.50
- Volume
- $1.90B
- Avg Volume
- $2.24B
- Shares Outstanding
- 57.0M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- -3.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.96
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +155.5%
Why Investors Own WHWK
- ✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
WHITEHAWK THERAPEUTICS INC
WHWKFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$7M▼ −72.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
89.4%▼ −182.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$114M▲ +69.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$98M▲ +60.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
69.2M▲ +155.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$38M▲ +$10M YoY
StockOtter · stockotter.spaceAbout WHITEHAWK THERAPEUTICS INC
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100
Analyst Price Target
ⓘAverage Target
$594.29
▲ +12.6% Upside
High Target$702.72
Low Target$508.37
Based on 32 analysts
Latest News & Updates
🚀
Reuters·2h ago
WHITEHAWK THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift WHWK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
WHITEHAWK THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.